| Name | Title | Contact Details |
|---|
SutroVax is a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases. SutroVax`s lead product candidate is a pneumococcal conjugate vaccine (PCV) that is designed to prevent invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae. SutroVax`s broad-spectrum PCV is designed to provide expanded protection against circulating strains of pneumococcus and has the potential to replace the current vaccines used in infants and adults. The current mainstay vaccine only covers approximately 40% of the circulating strains causing IPD yet generates $6B in annual sales. SutroVax has generated positive pre-clinical proof-of-concept with its significantly broader-spectrum PCV compared head-to-head to current vaccines using well accepted immunological endpoints. In addition to its lead PCV product candidate, the Company also has a promising early-stage pipeline addressing other important disease areas. SutroVax`s conjugate vaccines are developed utilizing the Company`s exclusive rights to Sutro Biopharma`s Xpress CF Platform, a cell-free protein synthesis technology. SutroVax closed its $85M Series C round in May of 2018 and is financed by a world-class syndicate of private equity, venture capital and corporate venture investors with over $170M in capital raised since 2015.
Ciitizen is a platform that helps you collect, organize, and share your medical records digitally. Use it to get a second opinion, coordinate with a caregiver, and donate to research.
Our solution: Segra leverages expertise in biochemistry, botany, plant tissue culture, genetic testing, and production under strict regulatory environments to bring end-to-end solutions for product production and sale in the medical Cannabis space.
Dova is a clinical-stage pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet medical need. With a nimble approach and a team of bright minds aglow with passion, we’re...
Protagonist Therapeutics is a biotechnology company pursuing the discovery and development of target oral peptides as well differentiated alternatives to antibodies, and also as new chemical entities (NCEs) against those targets and life threatening diseases for which suitable small molecule and/or biologic options are not available. Peptides typically suffer from limitations of poor proteolytic stability and therefore find scarce therapeutic utility that is largely limited to ‘injectable drugs’. Protagonist’s technology platform is aimed at overcoming these restrictions and expanding the scope of peptide therapeutics to address unmet needs. Specific emphasis is placed on identifying ‘orally stable’ scaffolds and/or engineering oral stability characteristics onto them. The platform has been optimized over the years and involves synergistic integration of rational drug design, diversity oriented computational tools, phage display libraries, recombinant peptide expression, ex vivo oral stability methods, and peptide/medicinal chemistry techniques. This activity has led to the identification of ‘privileged scaffolds’ with favorable oral stability characteristics. Furthermore, the technology platform is well suited both for de novo discovery against a target and optimization around a given chemical starting point.